US 10059762
Anti-EGFR activatable antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10059762 (Anti-EGFR activatable antibodies) held by CytomX Therapeutics, Inc. expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 41
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K47/6845